Advanced Oncotherapy (AVO) – Exercise of warrants and options and issue of shares

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has agreed to issue 7,166,667 new ordinary shares  of 1p in the Company to Dr. Nick Plowman, Chairman of the Medical Advisory Board, pursuant to the exercise of warrants and options at prices between 1.1 pence and 5 pence.

Application will be made for the 7,166,667 new Ordinary Shares to be admitted to trading on AIM and it is expected that Admission will occur on or about 7 August 2015. The new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,418,328,375 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of Ordinary Shares in the Company with voting rights will be 1,418,328,375. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact: